Mediastinal staging lymph node probability map in non-small cell lung cancer

Other authors

[Bordas-Martinez J] Pulmonology Department, Hospital General de Granollers, Granollers, Spain. Pulmonology Department, Bellvitge Universitary Hospital, UB, IDIBELL, CIBERES, Barcelona, Spain. [Vercher-Conejero JL, Notta PC] Nuclear Medicine Department – PET-CT, ICS-IDI, UB, Bellvitge Universitary Hospital, IDIBELL, Barcelona, Spain. [Rodriguez-González G, Martin Cabeza C, Cortes-Romera M] Pulmonology Department, Hospital General de Granollers, Granollers, Spain. [Cubero N] Pulmonology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain

Hospital General de Granollers

Publication date

2025-07-01T11:02:00Z

2025-07-01T11:02:00Z

2025-03-24



Abstract

Lung cancer; Lymph node; Mediastinal staging


Cáncer de pulmón; Ganglio linfático; Estadificación mediastínica


Càncer de pulmó; Gangli limfàtic; Escenificació mediastínica


Background: Mediastinal lymph node (LN) staging is routinely performed using PET/CT and EBUS-TBNA. Promising predictive algorithms for lymph nodes have been reported for each technique, both individually and in combination. This study aims to develop a predictive algorithm that combines EBUS, PET/CT and clinical data to provide a probability of malignancy. Methods: A retrospective study was conducted on consecutive patients with non-small cell lung carcinoma staged using PET/CT and EBUS-TBNA. Lymph nodes were identified by level (N1, N2, and N3) and anatomical region (AR) (subcarinal, paratracheal, and hilar). A Standardized Uptake Value (SUV) was determined for each sampled LN. The ultrasound features collected included diameter in the short axis (DSA), morphology, border, echogenicity and the presence of the vascular hilum. A robust logistic regression model was used to construct an algorithm to estimate the probability of malignancy of the lymph node. Results: A total of 116 patients with a mean age of 66, 93% of whom were men, were included. 358 lymph nodes were evaluated, 51% of which exhibited adenocarcinoma and 35% were squamous, while 14% were classified as non-small-cell lung carcinoma. The model estimated the probability of malignancy for each lymph node using age, DSA, SUVmax, and AR. The Area Under the ROC curve, was 0.89. A user-friendly application was also developed ( https://ubidi.shinyapps.io/lymma/ .) CONCLUSIONS: The integration of patient clinical characteristics, EBUS features, and PET/CT findings may generate a pre-sampling malignancy probability map for each lymph node. The model requires prospective and external validation.

Document Type

Article


Published version

Language

English

Publisher

BMC

Related items

Respiratory research;26(1)

https://doi.org/10.1186/s12931-025-03121-z

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)